323 related articles for article (PubMed ID: 31102009)
1. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
Takahari D; Chin K; Ishizuka N; Takashima A; Minashi K; Kadowaki S; Nishina T; Nakajima TE; Amagai K; Machida N; Goto M; Taku K; Wakatsuki T; Shoji H; Hironaka S; Boku N; Yamaguchi K
Gastric Cancer; 2019 Nov; 22(6):1238-1246. PubMed ID: 31102009
[TBL] [Abstract][Full Text] [Related]
2. Multicenter phase II study of SOX plus trastuzumab for patients with HER2
Yuki S; Shinozaki K; Kashiwada T; Kusumoto T; Iwatsuki M; Satake H; Kobayashi K; Esaki T; Nakashima Y; Kawanaka H; Emi Y; Komatsu Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Baba H; Mori M
Cancer Chemother Pharmacol; 2020 Jan; 85(1):217-223. PubMed ID: 31768696
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; Matsusaka S; Segawa Y; Nakamura M; Sasaki K; Nagao N; Hatachi Y; Yuasa Y; Asami S; Takeuchi M; Furukawa H; Nakajima T;
Gastric Cancer; 2018 May; 21(3):421-427. PubMed ID: 28936560
[TBL] [Abstract][Full Text] [Related]
4. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
[TBL] [Abstract][Full Text] [Related]
5. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
[TBL] [Abstract][Full Text] [Related]
6. Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer.
Mori Y; Kataoka H; Ebi M; Adachi K; Yamaguchi Y; Hayashi N; Hirata Y; Sobue S; Ishihara R; Suzuki Y; Mizushima T; Inoue Y; Hasegawa I; Ono S; Hirano A; Kimura Y; Seno K; Ozeki K; Shimura T; Kubota E
J Gastrointest Cancer; 2022 Dec; 53(4):930-938. PubMed ID: 34550548
[TBL] [Abstract][Full Text] [Related]
7. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of S-1 plus oxaliplatin 130 mg/m
Kashiwada T; Shinozaki K; Ueno S; Kawanaka H; Uno F; Okita Y; Fukahori M; Matsushita H; Emi Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Maehara Y; Mori M; Baba E;
Int J Clin Oncol; 2021 Feb; 26(2):345-354. PubMed ID: 33085058
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
Ryu MH; Yoo C; Kim JG; Ryoo BY; Park YS; Park SR; Han HS; Chung IJ; Song EK; Lee KH; Kang SY; Kang YK
Eur J Cancer; 2015 Mar; 51(4):482-488. PubMed ID: 25661103
[TBL] [Abstract][Full Text] [Related]
10. A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
Kagawa S; Muraoka A; Kambara T; Nakayama H; Hamano R; Tanaka N; Noma K; Tanakaya K; Kishimoto H; Shigeyasu K; Kuroda S; Kikuchi S; Kuwada K; Nishizaki M; Shirakawa Y; Fujiwara T
Cancer Chemother Pharmacol; 2018 Feb; 81(2):387-392. PubMed ID: 29290024
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).
Kurokawa Y; Sugimoto N; Miwa H; Tsuda M; Nishina S; Okuda H; Imamura H; Gamoh M; Sakai D; Shimokawa T; Komatsu Y; Doki Y; Tsujinaka T; Furukawa H
Br J Cancer; 2014 Mar; 110(5):1163-8. PubMed ID: 24473399
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
[TBL] [Abstract][Full Text] [Related]
14. Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab.
Wakatsuki T; Ishizuka N; Hironaka S; Minashi K; Kadowaki S; Goto M; Shoji H; Hirano H; Nakayama I; Osumi H; Ogura M; Chin K; Yamaguchi K; Takahari D
Int J Clin Oncol; 2024 Jun; 29(6):801-812. PubMed ID: 38589679
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.
Endo S; Kurokawa Y; Gamoh M; Kimura Y; Matsuyama J; Taniguchi H; Takeno A; Kawabata R; Kawada J; Masuzawa T; Yamamoto K; Kobayashi K; Sakai D; Shimokawa T; Satoh T
Anticancer Res; 2019 Feb; 39(2):1059-1065. PubMed ID: 30711995
[TBL] [Abstract][Full Text] [Related]
16. Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.
Saeki H; Emi Y; Oki E; Tokunaga S; Kakeji Y; Akagi Y; Baba H; Baba E; Maehara Y;
BMC Cancer; 2018 Jan; 18(1):57. PubMed ID: 29310611
[TBL] [Abstract][Full Text] [Related]
17. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
Jiang Z; Zhou A; Sun Y; Zhang W
BMC Cancer; 2022 Mar; 22(1):253. PubMed ID: 35264150
[TBL] [Abstract][Full Text] [Related]
18. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
[TBL] [Abstract][Full Text] [Related]
19. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I
Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial).
Lee KW; Chung IJ; Ryu MH; Park YI; Nam BH; Oh HS; Lee KH; Han HS; Seo BG; Jo JC; Lee HR; Kim JW; Park SR; Cho SH; Kang YK;
Gastric Cancer; 2021 Jan; 24(1):156-167. PubMed ID: 32596783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
